专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180042952A1 ETOPOSIDE AND PRODRUGS THEREOF FOR USE IN TARGETING CANCER STEM CELLS 审中-公开
公开(公告)号：US20180042952A1
公开(公告)日：2018-02-15
申请号：US15794470
申请日：2017-10-26
申请人： CELLACT PHARMA GMBH
发明人： Nalan UTKU , Steven R. GULLANS
IPC分类号： A61K31/7048 , A61K45/06
CPC分类号： A61K31/7048 , A61K45/06
摘要： The present invention pertains to the use of podophyllotoxin derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.

2. 发明授权

US11892454B2 Method for the diagnosis of etoposide prodrug treatable cancer 有权
公开(公告)号：US11892454B2
公开(公告)日：2024-02-06
申请号：US16110007
申请日：2018-08-23
申请人： CellAct Pharma GMBH
发明人： Nalan Utku
IPC分类号： G01N31/00 , G01N33/53 , G01N33/574 , A61K31/7048 , C12Q1/6886
CPC分类号： G01N33/57438 , A61K31/7048 , C12Q1/6886 , G01N33/57407 , G01N33/57419 , C12Q2600/106 , C12Q2600/158 , G01N2333/918 , G01N2800/52
摘要： The present invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods of the invention include the analysis of carboxyelesterase 2 (CES2)-expression in tumor samples as a predictive value for the assessment of treatment success with an ester-prodrug of a chemotherapeutic agent. Alternatively, the invention provides methods involving the analysis of the urinary ratio of the prodrug and the active therapeutic as another predictive value for assessing treatment susceptibility.

3. 发明公开

US20230398069A1 ETOPOSIDE TONIRIBATE FORMULATION 审中-公开
公开(公告)号：US20230398069A1
公开(公告)日：2023-12-14
申请号：US18022353
申请日：2021-08-19
申请人： CELLACT PHARMA GMBH
发明人： Davide GUGGI , Anna MONTES VÁZQUEZ , Javier MARTÍNEZ RUBIO , Rudy THOMA
IPC分类号： A61K9/08 , A61K31/7048 , A61K47/26 , A61K47/10 , A61K9/00 , A61K47/02
CPC分类号： A61K9/08 , A61K31/7048 , A61K47/26 , A61K47/10 , A61K9/0019 , A61K47/02
摘要： A liquid pharmaceutical formulation comprising etoposide toniribate; a polysorbate; and ethanol. A method of preparing an infusion solution comprising diluting said liquid pharmaceutical formulation. Said composition or solution for use in treating cancer in a patient in need thereof.

4. 发明申请

US20190086418A1 METHOD FOR THE DIAGNOSIS OF ETOPOSIDE PRODRUG TREATABLE CANCER 审中-公开
公开(公告)号：US20190086418A1
公开(公告)日：2019-03-21
申请号：US16110007
申请日：2018-08-23
申请人： CellAct Pharma GMBH
发明人： Nalan Utku
IPC分类号： G01N33/574 , A61K31/7048 , C12Q1/6886
摘要： The present invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods of the invention include the analysis of carboxyelesterase 2 (CES2)-expression in tumor samples as a predictive value for the assessment of treatment success with an ester-prodrug of a chemotherapeutic agent. Alternatively, the invention provides methods involving the analysis of the urinary ratio of the prodrug and the active therapeutic as another predictive value for assessing treatment susceptibility.

5. 发明授权

US10183035B2 Etoposide and prodrugs thereof for use in targeting cancer stem cells 有权
公开(公告)号：US10183035B2
公开(公告)日：2019-01-22
申请号：US15794470
申请日：2017-10-26
申请人： CELLACT PHARMA GMBH
发明人： Nalan Utku , Steven R. Gullans
IPC分类号： A61K31/7048 , A61K45/06
摘要： The present invention pertains to the use of podophyllotoxin derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.

6. 发明申请

US20180125873A1 ANALOGUES OF ETOPOSIDE FOR THE TREATMENT OF TUMOURS 审中-公开
公开(公告)号：US20180125873A1
公开(公告)日：2018-05-10
申请号：US15865818
申请日：2018-01-09
申请人： CellAct Pharma GmbH
发明人： Nalan UTKU
IPC分类号： A61K31/7048 , C07H17/04 , A61K45/06 , A61K31/704
摘要： Compounds for treatment of a patient having a tumour that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula: wherein X is O, NH and S, wherein n is 0, 1 or 2, wherein R1 and R2 are H, methyl or ethyl, or together form a group CR3R4, and wherein R3 and R4 are H, methyl or ethyl.

7. 发明授权

US09827261B2 Etoposide and prodrugs thereof for use in targeting cancer stem cells 有权
公开(公告)号：US09827261B2
公开(公告)日：2017-11-28
申请号：US14775707
申请日：2014-03-12
申请人： CELLACT PHARMA GMBH
发明人： Nalan Utku , Steven R. Gullans
IPC分类号： A61K31/7048 , A61K45/06
CPC分类号： A61K31/7048 , A61K45/06
摘要： The present invention pertains to the use of podophyllotox in derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.

8. 发明申请

US20160022721A1 ETOPOSIDE AND PRODRUGS THEREOF FOR USE IN TARGETING CANCER STEM CELLS 有权
标题翻译：用于靶向癌细胞的ETOPOSIDE及其产物
公开(公告)号：US20160022721A1
公开(公告)日：2016-01-28
申请号：US14775707
申请日：2014-03-12
申请人： CELLACT PHARMA GMBH
发明人： Nalan UTKU , Steven R. GULLANS
IPC分类号： A61K31/7048 , A61K45/06
CPC分类号： A61K31/7048 , A61K45/06
摘要： The present invention pertains to the use of podophyllotox in derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.
摘要翻译：本发明涉及用于抑制和/或预防癌症干细胞生长和/或存活的方法中鬼臼毒素在诸如CAP7.1的衍生物中的用途。本发明公开了根据本发明的化合物对癌症干细胞群体的惊人比活性。在这方面，本发明提供了治疗癌症，特别是具有发生转移，化疗抗性和/或癌症复发的高风险的癌症中所述的化合物的用途。提供了新的癌症治疗方法，以及包含所述化合物的药物组合物，用于这种治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式